Literature DB >> 15860583

Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.

Ekambar R Kandimalla1, Lakshmi Bhagat, Yukui Li, Dong Yu, Daqing Wang, Yan-Ping Cong, Sam S Song, Jimmy X Tang, Tim Sullivan, Sudhir Agrawal.   

Abstract

Bacterial DNA and synthetic oligomers containing CpG dinucleotides activate the immune system through Toll-like receptor (TLR) 9. Here, we compare the immunostimulatory activity of three immunomers with different nucleotide sequences containing a synthetic cytosine-phosphate-2'-deoxy-7-deazaguanosine dinucleotide (CpR), called immunomodulatory oligonucleotides (IMOs), in mouse, human, and monkey systems. IMOs induced IL-12 and IFN-gamma secretion more than a control non-CpG IMO in mice. All three IMOs activated HEK293 cells expressing TLR9 but not TLR3, -7, or -8. IMOs induced human B-cell proliferation and enhanced expression of CD86 and CD69 surface markers on B cells. The three IMOs induced CD86 expression on human plasmacytoid dendritic cells, but only IMOs that contained a 5'-terminal TCR nucleotide sequence induced IFN-alpha secretion. A sequence that forms a duplex structure also was required for IFN-alpha induction in human peripheral blood mononuclear cell cultures. IMOs induced chemokine and cytokine gene expression in human peripheral blood mononuclear cells. In monkeys, all three IMOs induced transient changes in peripheral blood leukocytes and lymphocytes and activated B and T lymphocytes. All three IMOs induced IFN-alpha in vivo in monkeys; the IMO sequence that forms a stable secondary structure induced the highest levels of IFN-alpha. These studies are, to our knowledge, the first comprehensive studies to compare the activity of IMOs containing synthetic stimulatory CpR dinucleotides in mouse, monkey, and human systems. These results suggest that IMOs induce strong and rapid immunostimulation and that the CpR dinucleotide is recognized by TLR9, leading to immune-cell activation and cytokine secretion in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860583      PMCID: PMC1100782          DOI: 10.1073/pnas.0501729102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity.

Authors:  D Yu; Q Zhao; E R Kandimalla; S Agrawal
Journal:  Bioorg Med Chem Lett       Date:  2000-12-04       Impact factor: 2.823

2.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

3.  CpG oligonucleotides with modified termini and nicked dumbbell structure show enhanced immunostimulatory activity.

Authors:  Sukunath Narayanan; Alexander H Dalpke; Karsten Siegmund; Klaus Heeg; Clemens Richert
Journal:  J Med Chem       Date:  2003-11-06       Impact factor: 7.446

4.  Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity.

Authors:  Q Zhao; D Yu; S Agrawal
Journal:  Bioorg Med Chem Lett       Date:  1999-12-20       Impact factor: 2.823

5.  Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages.

Authors:  Dong Yu; Ekambar R Kandimalla; Qiuyan Zhao; Yanping Cong; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

6.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

7.  Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages.

Authors:  D Yu; E R Kandimalla; Q Zhao; Y Cong; S Agrawal
Journal:  Bioorg Med Chem       Date:  2001-11       Impact factor: 3.641

8.  Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases.

Authors:  D Yu; E R Kandimalla; Q Zhao; Y Cong; S Agrawal
Journal:  Bioorg Med Chem Lett       Date:  2001-09-03       Impact factor: 2.823

9.  Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties.

Authors:  Dong Yu; Fu-Gang Zhu; Lakshmi Bhagat; Hui Wang; Ekambar R Kandimalla; Ruiwen Zhang; Sudhir Agrawal
Journal:  Biochem Biophys Res Commun       Date:  2002-09-13       Impact factor: 3.575

Review 10.  Antisense and/or immunostimulatory oligonucleotide therapeutics.

Authors:  S Agrawal; E R Kandimalla
Journal:  Curr Cancer Drug Targets       Date:  2001-11       Impact factor: 3.428

View more
  26 in total

Review 1.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

2.  Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.

Authors:  Mallikarjuna R Putta; Lakshmi Bhagat; Daqing Wang; Fu-Gang Zhu; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  ACS Med Chem Lett       Date:  2013-01-29       Impact factor: 4.345

3.  Novel drugs targeting Toll-like receptors for antiviral therapy.

Authors:  Mira C Patel; Kari Ann Shirey; Lioubov M Pletneva; Marina S Boukhvalova; Alfredo Garzino-Demo; Stefanie N Vogel; Jorge Cg Blanco
Journal:  Future Virol       Date:  2014-09       Impact factor: 1.831

Review 4.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

Review 5.  Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.

Authors:  Xiaopei Huang; Yiping Yang
Journal:  Expert Opin Ther Targets       Date:  2010-08       Impact factor: 6.902

6.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

7.  Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates.

Authors:  Sridhar Dharmapuri; Daniela Peruzzi; Carmela Mennuni; Francesco Calvaruso; Saverio Giampaoli; Gaetano Barbato; Ekambar R Kandimalla; Sudhir Agrawal; Elisa Scarselli; Giuseppe Mesiti; Gennaro Ciliberto; Nicola La Monica; Luigi Aurisicchio
Journal:  Mol Ther       Date:  2009-07-21       Impact factor: 11.454

8.  Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.

Authors:  Dong Yu; Mallikarjuna R Putta; Lakshmi Bhagat; Meiru Dai; Daqing Wang; Anthony F Trombino; Tim Sullivan; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

Review 9.  Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Authors:  Kristina Iribarren; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Špíšek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-09-02       Impact factor: 8.110

10.  Toll-like receptor 9-dependent activation of myeloid dendritic cells by Deoxynucleic acids from Candida albicans.

Authors:  Akiko Miyazato; Kiwamu Nakamura; Natsuo Yamamoto; Héctor M Mora-Montes; Misuzu Tanaka; Yuzuru Abe; Daiki Tanno; Ken Inden; Xiao Gang; Keiko Ishii; Kiyoshi Takeda; Shizuo Akira; Shinobu Saijo; Yoichiro Iwakura; Yoshiyuki Adachi; Naohito Ohno; Kotaro Mitsutake; Neil A R Gow; Mitsuo Kaku; Kazuyoshi Kawakami
Journal:  Infect Immun       Date:  2009-05-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.